At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 265 enrolled
Drug / intervention
Voclosporin High Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
In Brief
A Phase 2 clinical trial evaluating Voclosporin High Dose, Voclosporin Low Dose, and 1 other intervention for Lupus Nephritis. Completed, enrolled 265 participants across 86 sites in 20 countries.
Detailed Summary
To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Nephritis
CountriesBangladesh, Belarus, Bulgaria, China, Ecuador, Georgia, Guatemala, Mexico, Philippines, Poland, Russia, Serbia, Singapore, South Korea, Spain, Sri Lanka, Taiwan, Thailand, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJun 2014
Primary CompletionJul 2016
Study CompletionJan 2017
TodayJul 2026
First PostedMay 19, 2014
Enrollment StartJun 1, 2014
Primary CompletionJul 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.1 years ago
Interventions
Voclosporin High Dosedrug
Voclosporin Low Dosedrug
Placebodrug